[go: up one dir, main page]

LT3233843T - Izoksazolo hidroksamido rūgšties junginiai, kaip lpxc inhibitoriai - Google Patents

Izoksazolo hidroksamido rūgšties junginiai, kaip lpxc inhibitoriai

Info

Publication number
LT3233843T
LT3233843T LT15816893T LT15816893T LT3233843T LT 3233843 T LT3233843 T LT 3233843T LT 15816893 T LT15816893 T LT 15816893T LT 15816893 T LT15816893 T LT 15816893T LT 3233843 T LT3233843 T LT 3233843T
Authority
LT
Lithuania
Prior art keywords
acid compounds
hydroxamic acid
lpxc inhibitors
isoxazole
isoxazole hydroxamic
Prior art date
Application number
LT15816893T
Other languages
English (en)
Inventor
Jiping Fu
Xianming Jin
Subramanian Karur
Guillaume Lapointe
Ann Marie Madera
Zachary Kevin Sweeney
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3233843T publication Critical patent/LT3233843T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LT15816893T 2014-12-16 2015-12-15 Izoksazolo hidroksamido rūgšties junginiai, kaip lpxc inhibitoriai LT3233843T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462092402P 2014-12-16 2014-12-16
PCT/IB2015/059631 WO2016097995A1 (en) 2014-12-16 2015-12-15 Isoxazole hydroxamic acid compounds as lpxc inhibitors

Publications (1)

Publication Number Publication Date
LT3233843T true LT3233843T (lt) 2019-12-10

Family

ID=55025302

Family Applications (1)

Application Number Title Priority Date Filing Date
LT15816893T LT3233843T (lt) 2014-12-16 2015-12-15 Izoksazolo hidroksamido rūgšties junginiai, kaip lpxc inhibitoriai

Country Status (42)

Country Link
US (3) US9549916B2 (lt)
EP (1) EP3233843B1 (lt)
JP (1) JP6697466B2 (lt)
KR (1) KR20170094214A (lt)
CN (1) CN107001295B (lt)
AR (1) AR107428A1 (lt)
AU (1) AU2015365455B2 (lt)
BR (1) BR112017011422A2 (lt)
CA (1) CA2969803A1 (lt)
CL (1) CL2017001460A1 (lt)
CO (1) CO2017005870A2 (lt)
CR (1) CR20170260A (lt)
CU (1) CU24443B1 (lt)
CY (1) CY1122305T1 (lt)
DK (1) DK3233843T3 (lt)
EA (1) EA032138B1 (lt)
EC (1) ECSP17045737A (lt)
ES (1) ES2756300T3 (lt)
GT (1) GT201700132A (lt)
HR (1) HRP20192009T1 (lt)
HU (1) HUE047225T2 (lt)
IL (1) IL252373B (lt)
JO (1) JO3818B1 (lt)
LT (1) LT3233843T (lt)
MA (1) MA41185B1 (lt)
ME (1) ME03546B (lt)
MX (1) MX2017007980A (lt)
MY (1) MY195743A (lt)
PE (1) PE20171044A1 (lt)
PH (1) PH12017501019B1 (lt)
PL (1) PL3233843T3 (lt)
PT (1) PT3233843T (lt)
RS (1) RS59507B1 (lt)
SG (1) SG11201704053WA (lt)
SI (1) SI3233843T1 (lt)
SM (1) SMT201900631T1 (lt)
SV (1) SV2017005462A (lt)
TN (1) TN2017000207A1 (lt)
TW (1) TWI693215B (lt)
UA (1) UA121225C2 (lt)
UY (1) UY36448A (lt)
WO (1) WO2016097995A1 (lt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117830C2 (uk) 2013-05-17 2018-10-10 Інсайт Корпорейшн Похідні біпіразолу як інгібітори jak
CA3026356A1 (en) * 2016-06-14 2017-12-21 Novartis Ag Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
CN107434766A (zh) * 2017-08-09 2017-12-05 凯莱英医药集团（天津）股份有限公司 烷烃羟胺类化合物的合成装置及连续合成方法
BR122023022189A2 (pt) 2018-02-16 2024-02-20 Incyte Corporation Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
AU2019345150A1 (en) 2018-09-20 2021-05-13 Blacksmith Medicines, Inc. Antibacterial compounds
MX2021005966A (es) * 2018-11-21 2021-07-06 Taisho Pharmaceutical Co Ltd Nuevo derivado de imidazol.
IL298118B1 (en) 2020-06-02 2025-10-01 Incyte Corp Processes for preparing JAK1 inhibitor
WO2022125670A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
CN112603936B (zh) * 2020-12-28 2022-08-02 仲恺农业工程学院 一种抑制气单胞菌属的组合物及其制备方法与应用
WO2022173758A1 (en) * 2021-02-11 2022-08-18 Forge Therapeutics, Inc. Antibacterial compounds
CN117279898A (zh) * 2021-02-11 2023-12-22 布莱克史密斯医药公司 抗菌化合物
DK4333840T3 (da) 2021-05-03 2025-11-24 Incyte Corp Jak1-vejinhibitorer til behandling af prurigo nodularis
MX2024003859A (es) * 2021-09-28 2024-05-21 Blacksmith Medicines Inc Inhibidores de lpxc y usos de estos.
WO2024067812A1 (zh) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途
WO2024067813A1 (zh) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和其医药上的用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381783D1 (de) 1982-03-03 1990-09-13 Genentech Inc Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
EP0418667B1 (de) 1989-09-22 1995-08-16 BASF Aktiengesellschaft Carbonsäureamide
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998006842A1 (en) 1996-08-16 1998-02-19 Schering Corporation Mammalian cell surface antigens; related reagents
US6509173B1 (en) 1997-10-21 2003-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
AU6085700A (en) 1999-07-12 2001-01-30 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
SG2012000667A (en) * 2003-01-08 2015-03-30 Univ Washington Antibacterial agents
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
NZ543654A (en) 2003-05-23 2009-05-31 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
ES2657443T3 (es) 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
PL2242773T3 (pl) 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
EP2927240A1 (en) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
EP2334636A2 (en) 2008-09-19 2011-06-22 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
CA2772613C (en) 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
CA2774250C (en) * 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
PL2512474T3 (pl) * 2009-12-16 2015-03-31 Pfizer N-przyłączone pochodne kwasu hydroksamowego użyteczne jako środki przeciwbakteryjne
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
MX2013005200A (es) 2010-11-10 2013-06-28 Achaogen Inc Derivados de acido hidroxamico y su so en el tratamiento de infecciones bacterianas.
AP3336A (en) 2011-03-07 2015-07-31 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
CN103717582B (zh) * 2011-04-08 2015-09-30 辉瑞大药厂 用作抗菌剂的异*唑衍生物
SG193458A1 (en) * 2011-04-08 2013-10-30 Pfizer Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections

Also Published As

Publication number Publication date
CA2969803A1 (en) 2016-06-23
CY1122305T1 (el) 2021-01-27
CO2017005870A2 (es) 2017-10-20
UA121225C2 (uk) 2020-04-27
CU24443B1 (es) 2019-10-04
HUE047225T2 (hu) 2020-04-28
CN107001295A (zh) 2017-08-01
RS59507B1 (sr) 2019-12-31
US20180030004A1 (en) 2018-02-01
AR107428A1 (es) 2018-05-02
ME03546B (me) 2020-07-20
SV2017005462A (es) 2018-04-04
ECSP17045737A (es) 2019-02-28
PH12017501019A1 (en) 2017-12-04
IL252373A0 (en) 2017-07-31
SG11201704053WA (en) 2017-06-29
US20170088525A1 (en) 2017-03-30
AU2015365455B2 (en) 2019-01-17
BR112017011422A2 (pt) 2018-04-03
SI3233843T1 (sl) 2019-12-31
PL3233843T3 (pl) 2020-04-30
SMT201900631T1 (it) 2020-01-14
GT201700132A (es) 2019-10-10
WO2016097995A1 (en) 2016-06-23
CR20170260A (es) 2017-08-21
CU20170084A7 (es) 2017-11-07
EA032138B1 (ru) 2019-04-30
MA41185B1 (fr) 2019-12-31
JO3818B1 (ar) 2021-01-31
US9549916B2 (en) 2017-01-24
EP3233843B1 (en) 2019-10-16
US10029994B2 (en) 2018-07-24
PT3233843T (pt) 2019-11-26
KR20170094214A (ko) 2017-08-17
US9815804B2 (en) 2017-11-14
TWI693215B (zh) 2020-05-11
TW201629024A (zh) 2016-08-16
JP2018500333A (ja) 2018-01-11
JP6697466B2 (ja) 2020-05-20
MX2017007980A (es) 2017-09-29
ES2756300T3 (es) 2020-04-27
IL252373B (en) 2019-11-28
DK3233843T3 (da) 2019-11-18
CN107001295B (zh) 2021-02-02
US20160166548A1 (en) 2016-06-16
MY195743A (en) 2023-02-08
EP3233843A1 (en) 2017-10-25
CL2017001460A1 (es) 2017-12-22
PH12017501019B1 (en) 2020-06-05
TN2017000207A1 (en) 2018-10-19
EA201791353A1 (ru) 2017-10-31
UY36448A (es) 2016-07-29
AU2015365455A1 (en) 2017-06-08
HRP20192009T1 (hr) 2020-02-07
PE20171044A1 (es) 2017-07-19

Similar Documents

Publication Publication Date Title
IL252373B (en) Hydrobromic acid isoxazole compounds as lpxc inhibitors
IL254721B (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
IL250876B (en) Inhibitors of specific lysine demethylase-1
IL248505A0 (en) Inhibitors of specific lysine demethylase-1
IL249733A0 (en) Inhibitors of specific lysine demethylase-1
IL249881B (en) Inhibitors of specific lysine demethylase-1
AP2016009496A0 (en) Substituted spirocydic inhibitors of autotaxin
ZA202001074B (en) Inhibitors of a-amino-b-carboxymuconic acid semialdehyde decarboxylase
IL249876A0 (en) Inhibitors of specific lysine demethylase-1
IL251780A0 (en) New compounds as nik inhibitors
GB2540917B (en) Solid acid scale inhibitors
EP3494971C0 (en) SALTS OF ERK INHIBITORS
ZA201700022B (en) A novel formulation of meloxicam
GB201403536D0 (en) Inhibitor compounds